Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: Case report and literature review of central nervous system pseudallescheriasis

Clinical Infectious Diseases

Volumn 31, Issue 3, 2000, Pages 673-677

  Nesky, M A ^a   McDougal, E C ^a   Peacock J E , Jr ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; ASCOMYCETES; BRAIN ABSCESS; CASE REPORT; HUMAN; MALE; MYCOSIS; PETRIELLIDIUM BOYDII; PRIORITY JOURNAL; PROGNOSIS; PSEUDALLESCHERIASIS; SKIN INFECTION; SURGICAL DRAINAGE;

ANTIFUNGAL AGENTS; BRAIN ABSCESS; CENTRAL NERVOUS SYSTEM; DRAINAGE; HUMANS; MALE; MIDDLE AGED; MYCOSES; PSEUDALLESCHERIA; PYRIMIDINES; TRIAZOLES;

EID: 0034457835     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314042     Document Type: Article

References (62)

1. Therapy of fungal meningitis
2. Candidal infection in the central nervous system
3. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome
4. Emerging fungal pathogens
5. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): An emerging mycosis
6. Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis and management
7. Near-drowning complicated by brain abscess due to Petriellidium boydii
8. Pseudallescheria boydii infection of the central nervous system
9. Petriellidium (Allescheria) boydii orbital and brain abscess treated with intravenous miconazole
10. Persistent neutrophilic meningitis clue to Pseudallescheria boydii
11. Maduromycotic meningitis
12. Allescheria boydii: Unique systemic dissemination to thyroid and brain
13. Allescheria boydii infection of the brain
14. Pachymeningitis secondary to Allescheria boydii
15. Isolation of Monosporium apiospermum from cerebrospinal fluid
16. Allescheria boydii infections in the immunocompromised host
17. Allescheria (Petriellidium) boydii brain abscess in a child with leukemia
18. Disseminated petriellidosis (allescheriosis)
19. Petriellidium boydii infection of the sphenoid sinus
20. A rare fungal brain abscess in an uncompromised host
21. An atypical isolate of Scedosporium apiospermum from a purulent meningitis in man
22. Disseminated petriellidiosis (allescheriasis) in a patient with refractory acute lymphoblastic leukemia
23. Brain abscess due to Petriellidium boydii
24. Petriellidium boydii pachymeningitis treated with miconazole and ketoconazole
25. Scedosporium (Monosporium) apiospermum: Multiple brain abscesses. Sabouraudia
26. Brain abscess due to Pseudallescheria boydii associated with primary non-Hodgkin's lymphoma of the central nervous system: A case report and literature review
27. Pseudallescheria boydii infection of the central nervous system in a cardiac transplant recipient
28. Brain abscess due to Scedosporium apiospermum in a renal transplant patient
29. Pseudallescheria boydii brain abscess: Complication of an intravenous catheter
30. Pseudallescheriasis
31. Pseudallescheria boydii brain abscess: Association with near-drowning and efficacy of high-dose, prolonged miconazole therapy in patients with multiple abscesses
32. Superior sagittal sinus infection with Petriellidium boydii: Case report
33. Cerebral Pseudallescheria boydii infection: Unique occurrence of fungus ball formation in the brain
34. Pseudallescheria boydii and brain abscesses
35. Monosporium apiospermum meningoencephalitis: A clinico-pathological case
36. Brain abscess following marrow transplantation: Experience at the Fred Hutchinson Cancer Research Center, 1984-1992
37. Pseudallescheria boydii infection of the brain: Imaging with pathologic confirmation
38. Fatal Pseudallescheria boydii panencephalitis in a child after a neardrowning
39. Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: A case of mistaken identity
40. Cerebral pseudallescheriasis due to Pseudallescheria boydii as the first manifestation of AIDS
41. Laboratory methods for the diagnosis and confirmation of systemic mycoses
42. Organ-specific variation in the morphology of the fungomas (fungus balls) of Pseudallescheria boydii
43. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report
44. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
45. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
46. Evolution of antifungal agents: Past, present, and future
47. A breast cancer patient with disseminated Scedosporium prolificans infection
48. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
49. Azole antifungal agents
50. Comment
51. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease
52. Scedosporium apiospermum skin infection: A case report and review of the literature
53. Pseudallescheria boydii infections treated with ketoconazole: Clinical evaluations of seven patients and in vitro susceptibility results
54. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier
55. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
56. Itraconazole therapy for chronic coccidioidal meningitis
57. In vivo efficacy of SM-8668 (Sch 39304), a new triazole antifungal agent
58. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole amphotericin B and griseofulvin
59. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
60. In vitro evaluation of voriconazole against some clinically important fungi
61. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
62. Current and emerging azole antifungal agents